Condition: Charcot-Marie-Tooth Disease · Sponsor: Flex Pharma, Inc.
The COMMIT Study will assess the safety and effectiveness of FLX-787 in men and women with Charcot-Marie-Tooth disease (CMT) experiencing muscle cramps. Participants will be asked to take two study products during the course of the study. One of these study products will be a placebo. Approximately 120 participants in 20 study centers across the United States are expected to take part. Participants will be in the study for approximately 3 months and visit the study clinic 3 times.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| Hospital for Special Care | New Britain, Connecticut, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Brighman and Women's Hospital | Boston, Massachusetts, United States | — |
| University of Minnesota | Minneapolis, Minnesota, United States | — |
| Saint Louis University | St Louis, Missouri, United States | — |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03254199